藥碼
MAR02
藥名
Bupivacaine HCl 5 mg/mL 4 mL
英文商品名
Marcaine重型 脊髓 常備0.5% 4 mL
中文商品名
麻佳因脊椎麻醉注射液(重型)
螢幕名
Marcaine重型 脊髓 常備0.5% 4 mL
劑型
Inj
規格
Inj 0.5% 4ml/amp (spinal)
成分
藥理分類
Local Anesthetics
健保碼
ATC碼
藥品圖片
外觀圖片
適應症
#高警訊藥品

It is indicated in adults and children of all ages for intrathecal (subarachnoid) spinal anaesthesia for surgery.
藥理
Local Anesthetic
Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction
藥動學
Onset of action:
1. Epidural: Up to 17 minutes to spread to T6 dermatome.
2. Spinal: Within 1 minute; maximum dermatome level achieved within 15 minutes in most cases.
Duration:
1. Epidural: 2 to 7.7 hours.
2. Spinal: 1.5 to 2.5 hours.
Distribution:
1. Vd: (Infants) 3.9 ± 2 L/kg; (Children) 2.7 ± 0.2 L/kg.
2. Protein binding: 84% to 95%.
Metabolism:
Hepatic; forms metabolite
Time to peak, plasma:
30 to 45 minutes
Excretion:
Urine (~6% unchanged); Clearance: (Infants) 7.1 ± 3.2 mL/kg/minute; Children: 10 ± 0.7 mL/kg/minute.
禁忌症
1. Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation
2. Obstetrical paracervical block anesthesia
3. IV regional anesthesia
懷孕分類
C
哺乳分類
Compatible with breastfeeding (WHO); Infant risk is minimal (MDX)
副作用
Hypotension, bradycardia, nausea, postdural puncture headache, vomiting, urinary retention, urinary incontinence
劑量和給藥方法
Injection site Dose (mg) Onset (minute) Duration (hour)
L3/4/5 7.5-15 mg 5-8 minutes 2-3 hours
L2/3/4 15-20 mg 5-8 minutes 1.5-2 hours
小兒調整劑量
1. Pediatric <5kg: 0.4-0.5 mg/kg
2. Pediatric 5-15kg: 0.3-0.4 mg/kg
3. Pediatric >15kg: 0.25-0.3 mg/kg
腎功能調整劑量
1. There are no specific dosage adjustments provided in the manufacturer's labeling.
2. Risk of adverse reactions may be increased in patients with renal impairment, particularly in patients with severe kidney disease. Consider increased monitoring for toxicities.
肝功能調整劑量
1.There are no specific dosage adjustments provided in the manufacturer's labeling.
2. Risk of toxicity may be increased in patients with severe impairment; consider a reduced dose and more frequent monitoring for toxicities in patients with moderate or severe impairment.
安定性
藥袋資訊
臨床用途
脊椎麻醉
主要副作用
泡製方法
儲存方式
注意事項
其他說明
單位常備藥,門診藥局不備庫 | 藥庫 公B22
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
自費價
155.61
仿單
資料庫
健保給付規定